DS-8201 is a novel HER2-targeted antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor [11], which has anti-cancer efficacy in clinical trials and anti-tumor immunity in mouse models [12]. This evidence concerns the gene ERBB2 and neoplasm.